A nested case-control study was conducted within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort to test for associations between selected B-vitamins (folate, vitamin B 6 , vitamin B 12 ) and incident lung cancer. This trial was conducted in Finland between 1985 and 1993. Serum was analyzed for these nutrients and homocysteine among 300 lung cancer cases and matched controls (1:1). Odds ratios and 95% confidence intervals were determined in conditional and unconditional (controlling for the matching factors) logistic regression models, after adjusting for body mass index, years of smoking, and number of cigarettes smoked per day. No significant associations were seen between serum folate, vitamin B 12 , or homocysteine and lung cancer risk. The authors found significantly lower risk of lung cancer among men who had higher serum vitamin B 6 levels. Compared with men with the lowest vitamin B 6 concentration, men in the fifth quintile had about one half of the risk of lung cancer (odds ratio = 0.51; 95% confidence interval: 0.23, 0.93; p-trend = 0.02). Adjusting for any of the other serum factors (folate, B 12 , and homocysteine) either alone or jointly did not significantly alter these estimates. This is the first report from a prospectively conducted study to suggest a role for vitamin B 6 in lung cancer. Am J Epidemiol 2001;153:688-94. folic acid; homocysteine; lung neoplasms; methylation; pyridoxine; vitamin B 12
Lung cancer is a major public health problem in Western countries. In Finland, it is one of the most common cancers, with approximately 1,500 new lung cancer cases diagnosed among men each year. The age-adjusted, standardized incidence rates for 1995 were 41.6/100,000 among men (1) . In the United States, the American Cancer Society estimated that there would be nearly 172,000 newly diagnosed lung cancer cases in 1999 (2) .
The B-vitamins folate, B 12 , and pyridoxal 5′-phosphate (B 6 ), the principal active form of vitamin B 6 , are precursors of the main coenzymes involved in the transfer of onecarbon groups essential for DNA synthesis and DNA methylation. Because of their involvement in these activities, these B-vitamins have been hypothesized to be associated with carcinogenesis. The roles of folate, vitamins B 6 and B 12 , and homocysteine in one-carbon metabolism have been reviewed in depth (3, 4) . Briefly, homocysteine is thought to have two primary metabolic fates, either conversion to methionine or catabolism via the transsulfuration pathway to cystathione and eventually cysteine. These two steps are facilitated by two vitamin B 6 -dependent enzymes, cystathionine beta-synthase and gamma-cystathionase. Cysteine is a main component for the synthesis of glutathione, an important cofactor of the glutathione Stransferases and glutathione peroxidases, which function in the detoxification of many toxic or carcinogenic compounds. Folate and vitamin B 12 function in the methylation of homocysteine to regenerate methionine. A large proportion of methionine is activated by adenosine 5′-triphosphate to produce S-adenosylmethionine, the primary methyl donor to nucleic acids, neurotransmitters, phospholipids, and hormones. Methylation is well recognized as a mechanism relevant to genomic structure and function (5) . Concomitant with methionine generation, tetrahydrofolate is formed that is converted to 5,10-methylenetetrahydrofolate, also facilitated by a vitamin B 6 -dependent enzyme, serine hydroxymethyl transferase. 5,10-Methylenetetrahydrofolate is required for the biosynthesis of purine nucleotides and thymidylate needed for DNA synthesis and repair (5) . Serum concentrations of folate, and to a lesser extent vitamins B 6 and B 12 , are inversely correlated with serum homocysteine concentrations (6) (7) (8) .
Previous studies have suggested a role for factors related to homocysteine metabolism in colon (9-13), breast (14, 15) , and pancreatic (16) cancer. We examined the association between these factors and lung cancer among male smokers who participated in a large clinical trial in southwestern Finland.
We conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. This trial was conducted in Finland between 1985 and 1993 as a joint project between the National Public Health Institute in Finland and the US National Cancer Institute. The trial was a large, randomized, double-blind, placebocontrolled prevention trial to determine whether daily supplementation with alpha-tocopherol, beta-carotene, or both would reduce the incidence of lung or other cancers. The overall design and initial results have been published (17, 18) . Briefly, 29,133 male smokers between the ages of 50 and 69 years were recruited from southwestern Finland between 1985 and 1988 and randomly assigned to one of four groups based on a 2 × 2 factorial design. Men who had prior cancer or serious illnesses or who reported current use of vitamins E (>20 mg/day), A (>20,000 IU/day), or betacarotene (>6 mg/day) were ineligible. Participants received alpha-tocopherol (50 mg/day) as dl-alpha-tocopheryl acetate, beta-carotene (20 mg/day), both alpha-tocopherol and beta-carotene, or placebo. Active follow-up continued for 5-8 years during the trial or until April 30, 1993 . Followup continued through the Finnish Cancer Registry and is ongoing. This clinical trial was approved by the institutional review boards of the National Cancer Institute and the National Public Health Institute of Finland.
Case ascertainment and control selection
The sample population for this analysis consisted of 300 incident lung cancer cases who were randomly selected from among those diagnosed during follow-up of the AlphaTocopherol, Beta Carotene Cancer Prevention Study and who also had a whole blood sample available for DNA extraction for related studies to be conducted within the same data set. Cases were identified by the Finnish Cancer Registry (19) . These were matched to 300 randomly selected controls who were cancer-free at the time of the case diagnosis on 1) age (up to ±5 years), 2) intervention group assignment, and 3) date of baseline blood collection (±28 days). The median follow-up for the group was 5.9 years.
Data collection and serum nutrient determination
At baseline, study participants completed a demographic, general medical history, and food frequency (use) questionnaire; height and weight were measured; and blood samples were collected. Information on smoking habits was collected at baseline and throughout the trial follow-up period. Data are available on the age at which smoking started, total years of smoking, number of cigarettes smoked per day, smoke inhalation (never, sometimes, often, always), and smoking cessation during active follow-up (yes/no at each visit). Serum samples were frozen at -70˚C. Samples were transported on dry ice to the Vitamin Metabolism Laboratory at the Jean Mayer US Department of Agriculture Human Nutrition Research Center at Tufts University, Boston, Massachusetts, for nutrient analysis.
Serum samples were analyzed for folate, pyridoxal 5′-phosphate, vitamin B 12 , and homocysteine. Homocysteine was determined using high performance liquid chromatography with fluorescence detection described by Araki and Sako (20) . Serum folate and B 12 were determined by radioassay using a commercial kit from Bio-Rad. Vitamin B 6 was determined by the tyrosine decarboxylase apoenzyme method of Shin-Buehring (21) . Matched sets were analyzed consecutively. Blind quality control samples were labeled to resemble the subject samples and were randomly placed within each batch. The overall coefficient of variation for quality control serum nutrients was 12 percent for folate, 10 percent for pyridoxal 5′-phosphate, 6 percent for vitamin B 12 , and 11 percent for homocysteine.
Statistical analysis
Statistical analyses were performed using Statistical Analysis System (SAS) software (22, 23) . The characteristics of case subjects and control subjects were compared by the nonparametric Wilcoxon rank sum test for continuous variables and by chi-squared tests for categorical variables. Odds ratios and 95 percent confidence intervals for the association between lung cancer and serum nutrients were determined in conditional and unconditional (controlling for the matching factors) logistic regression models. Serum nutrients were analyzed as both continuous natural logtransformed variables and categorical variables. To develop the categorical variables, serum nutrient values were grouped into quintiles based on the distribution among the controls and were entered into models as indicator variables defined by the second through fifth quintiles of intake, with the lowest quintile as the referent group. To conduct a linear trend test across levels of nutrients, we created variables using exposure scores based on the median values for each quintile of serum nutrients among the controls. Dietary variables of interest, including folate, vitamins B 6 and B 12 , methionine, alcohol, vitamin C, and fruit and vegetable intake, were also natural log transformed and in addition were adjusted for total energy intake according to the residual method of Willett and Stampfer (24) . Supplemental intake of vitamins and minerals of interest was added to dietary intake before transformation and energy adjustment. A three-level smoking cessation variable was created to reflect whether the participant did not quit, quit early during follow-up (<3 years), or quit late during follow-up (≥3 years). Cessation had to be maintained for at least two consecutive follow-up visits or 8 months. Variables included in the multivariate models were those that confounded the association between serum nutrients and lung cancer and those that were risk factors for lung cancer. All regression analyses were adjusted for potential confounding by smoking (years and number of cigarettes smoked per day as continuous variables) and body mass index (weight (kg)/height (m)
2 ). Results are reported as multivariate adjusted odds ratios of lung cancer with 95 percent confidence intervals.
Effect modification by intervention, age, body mass index, smoking, alcohol intake, and other serum nutrients was assessed by including the individual factor and its cross-product term with the continuous serum nutrient variable in a separate multivariate model and by stratified analysis. For stratified analyses, variables of interest were dichotomized based on the median, and the resulting subgroups were analyzed unmatched, controlling for the matching factors and important other covariates in the models. Table 1 shows selected characteristics of lung cancer cases and matched controls. The lung cancer cases were heavier smokers and had smoked for more years than the controls. In addition, the mean body mass index was significantly lower among cases compared with controls. Approximately 54 percent of the cases and controls in this study had less than adequate vitamin B 6 status (<30 nmol/liter), 90 percent had less than adequate folate status (<6 ng/ml), and only 2 percent had less than adequate vitamin B 12 status (<190 pmol/liter). Nearly one fourth of this population had elevated serum homocysteine levels (>15 µmol/liter). These results are sim- ilar to that of a pancreatic cancer study completed in this population, with the exception that only 15 percent of pancreatic cases and controls had hyperhomocysteinemia (16) . Serum concentrations of vitamins B 6 , B 12 , folate, and homocysteine were not highly correlated. The highest correlations were between serum levels of homocysteine and serum folate (r ϭ -0.32) and vitamin B 12 (r ϭ -0.20). The dietary intake and serum concentrations of these B-vitamins were not highly correlated, either. The correlation between dietary intake and the serum level for vitamin B 6 was 0.23; for vitamin B 12 , 0.10; and for folate, 0.26. Table 2 presents results from multivariate conditional regression models. After controlling for body mass index, years of smoking, and the number of cigarettes smoked per day, we found significantly lower risk of lung cancer among men who had higher serum vitamin B 6 12 , and homocysteine) either alone or jointly did not significantly alter these estimates. In addition, adjusting for dietary variables (e.g., fruit and vegetables, vitamin C, or total energy intake) or other smoking variables (year at which started smoking, smoke inhalation patterns, and smoking cessation during follow-up) did not significantly alter these estimates. We did not see any associations between levels of vitamin B 12 , folate, or homocysteine with lung cancer risk after controlling for vitamin B 6 and other covariates. Dietary vitamin B 6 , vitamin B 12 , and folate were only weakly associated with lung cancer, and a combination of low folate intake, low methionine intake, and high alcohol intake was not associated with lung cancer risk (data not shown).
RESULTS
There were no significant interactions between serum vitamin B 6 and serum folate level, alcohol intake, age, body mass index, or treatment group. The risk estimates for quintiles of serum vitamin B 6 stratified by factors known to affect methyl group availability (smoking, methionine and alcohol intake, and serum homocysteine, folate, and vitamin B 12 ) are shown in table 3. There was a statistically significant interaction between vitamin B 6 and smoking, with the protective effect of vitamin B 6 apparent only among those who had smoked longer. There was a statistically significant interaction between dietary methionine intake and serum vitamin B 6 , with a consistent pattern of decreasing risk of lung cancer with increasing serum vitamin B 6 concentration apparent only among those with lower methionine intakes. There was also a statistically significant interaction between serum vitamin B 6 and serum vitamin B 12 . This association, however, did not show a consistent doseresponse pattern in either stratum of vitamin B 12 . There was a marginally significant interaction between serum vitamin B 6 and serum homocysteine (p ϭ 0.05), with the suggestion that the protective effect of vitamin B 6 was stronger among men with higher homocysteine levels. In addition, although we observed no main effects for serum homocysteine con- centrations, among men with high serum vitamin B 6 levels, serum homocysteine was significantly inversely associated with lung cancer risk with a significant trend (p ϭ 0.007).
DISCUSSION
In this nested case-control study of lung cancer, we found an inverse association between the serum vitamin B 6 concentration and risk. Serum vitamin B 12 , folate, and homocysteine were not associated with lung cancer incidence.
Very few studies have evaluated the association between serum vitamin B 6 , vitamin B 12 , folate, or homocysteine and lung cancer. To our knowledge, no other study has evaluated these serum factors jointly in relation to lung cancer. Bandera et al. (25) reported an inverse association between dietary folate and lung cancer among men but not among women in the New York State cohort, and another casecontrol study found a nonsignificant inverse trend for folate intake and lung cancer (26) . In a case-control study conducted in Turkey, plasma B 12 levels were higher among lung cancer cases compared with controls, while levels of serum folate in those with lung cancer did not differ significantly from those of controls (27) . Heimburger et al. (28) evaluated whether folate and vitamin B 12 supplementation modified the severity of potentially premalignant lesions among 73 men with a history of 20 or more pack-years of cigarette smoking. Men who had taken supplements with folate and vitamin B 12 showed significantly greater reduction of atypia compared with men who received a placebo. This group also reported that plasma folate levels were lower in smokers with lung metaplasia than in smokers without metaplasia (28) .
The finding of an inverse association between serum vitamin B 6 and lung cancer is intriguing. There are several potential mechanisms by which vitamin B 6 may influence carcinogenesis. Vitamin B 6 is known to affect immunocompetence (29) (30) (31) (32) (33) . Some animal research also demonstrates that vitamin B 6 deficiency leads to greater lipid peroxidation in plasma and liver when the animal consumes a high fat diet (34, 35) . Vitamin B 6 also plays an important role in homocysteine metabolism serving a critical role in homocysteine catabolism. In the process of homocysteine catabolism, cysteine, a main component for the synthesis of glutathione, is generated. Glutathione serves as an important cofactor of the glutathione S-transferases and glutathione peroxidases, which function in the detoxification of many toxic or carcinogenic compounds (5, 36) . Decreased activity of these enzymes has been associated with increased DNA (37) . Vitamin B 6 may affect DNA synthesis through its intricate involvement with folic acid. Vitamin B 6 facilitates the transfer of a methyl group to tetrahydrofolate, yielding 5,10-methylenetetrahydrofolate needed for reactions generating thymidylate and purines. Thus, lower serum B 6 levels might lead to reduced DNA synthesis and impaired DNA repair (5, 36) . Further, disruption of these reactions may lead to imbalances in methyl groups required for methylation processes, including DNA methylation. Altered DNA methylation has been observed in tumors at several sites (36, 38) .
We observed that several other factors related to methyl group availability modified the protective effect observed for increasing serum vitamin B 6 status and lung cancer. For dietary methionine, serum vitamin B 12 , and serum homocysteine, the protective effects of vitamin B 6 were more apparent in the strata more likely to be susceptible to imbalances in methyl group availability for use in DNA methylation or synthesis (higher homocysteine, lower methionine, lower vitamin B 12 ). It is unclear why the protective effect of vitamin B 6 was more consistent among those who had smoked longer; however, cigarette smoking has been reported to affect vitamin B 6 status and is also known to interfere with folate and vitamin B 12 metabolism (39-41). The number of effect modifiers evaluated among these data dictate caution in interpreting these findings; however, these results appear internally consistent. We did not see any strong associations between dietary intake of B-vitamins and lung cancer in this study. The correlations between diet and serum markers in this population were somewhat lower than those observed by others. Willett et al. (42) reported correlations of 0.37 for both vitamin B 6 and vitamin B 12 . Jacques et al. (43) and Selhub et al. (44) reported correlations of 0.63 and 0.56, respectively, for folate. As noted above, smoking and alcohol are known to affect B-vitamin status and may have interfered with the metabolism of these nutrients in this population.
The prospective design of this study minimizes the potential for recall bias and the effects of disease on serum micronutrient measurements. Moreover, by measuring all three of the nutrients known to be important to homocysteine metabolism, we were able to adjust for their potential confounding and contribution to DNA synthesis, repair, or methylation via these pathways. Some issues should be considered when weighing the results of our study. These results may not be readily generalizable to other populations. Many men in this population had inadequate levels of folate and vitamin B 6 . All of the men in this population are smokers. Both smoking and alcohol have been inversely associated with both nutrients (45) (46) (47) (48) . It is also possible that we may not have captured the right time period to see an effect for the serum vitamins other than vitamin B 6 . Other studies should shed more light on this possibility. Low vitamin B 6 status may occur as a result of early, as yet undiagnosed lung cancer. While it is feasible that poorer vitamin B 6 status reflects subclinical disease, these results were unchanged when persons with cancers diagnosed during the first 2 years of follow-up were eliminated from the analysis. Theophylline, prescribed for lung disorders such as chronic bronchitis, asthma, and emphysema, is known to lower serum vitamin B 6 concentrations (49, 50). These three conditions have also been positively associated with lung cancer risk (51) . In these analyses, inclusion of a variable combining these lung conditions in the final models did not appreciably alter the risk estimates for vitamin B 6 .
In conclusion, our findings suggest an inverse association between vitamin B 6 and risk of lung cancer among older male smokers. We did not find evidence for a protective association between higher concentrations of serum folate or vitamin B 12 and decreased lung cancer. This is the first report of a protective effect of vitamin B 6 for lung cancer in a prospective study; therefore, the findings should be replicated in other populations. 
